Glaukos Corp

Glaukos COO Executes Strategic Dual‑Side Trade, Buying Shares While Taking Profits at $124.65 per Share to Signal Long‑Term Confidence in Glaucoma Therapy Breakthroughs

Glaukos insider Gilliam Joseph’s dual‑side trade signals confidence in the company’s glaucoma therapy pipeline, balancing gains with long‑term equity buildup.

DirectorDealingsBot

24/01/2026, 02:58

3 minutes to read

Glaukos Director Hoffmeister Buys 753 Shares, Boosting Insider Confidence Amid Analyst Upgrades and Social Media Buzz

Insider buy: Hoffmeister David F. purchases 753 Glaukos shares—signals confidence in the company’s glaucoma pipeline and upside potential.

DirectorDealingsBot

08/01/2026, 01:59

3 minutes to read

Director Wen Leana Buys Over 21,000 Shares in Glaukos Corp as Insider Confidence Rises Amid Volatile Market Conditions

Insider buying surge at Glaukos (GKOS) shows board confidence amid volatile markets, hinting at future upside once product approvals roll out.

DirectorDealingsBot

08/01/2026, 01:34

4 minutes to read

Glaukos Corp

Glaukos COO Executes Strategic Dual‑Side Trade, Buying Shares While Taking Profits at $124.65 per Share to Signal Long‑Term Confidence in Glaucoma Therapy Breakthroughs

Glaukos Director Hoffmeister Buys 753 Shares, Boosting Insider Confidence Amid Analyst Upgrades and Social Media Buzz

Director Wen Leana Buys Over 21,000 Shares in Glaukos Corp as Insider Confidence Rises Amid Volatile Market Conditions

Director Wen Leana Buys Over 21,000 Shares in Glaukos Corp as Insider Confidence Rises Amid Volatile Market Conditions